Statistiche di base
| CIK | 1555279 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to 908 Devices Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 5, 2025 |
Exhibit 99.1 908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook Revenue from continuing operations grew 14% compared to prior year BOSTON – August 5, 2025 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 4, 2025 |
Exhibit 99.1 908 Devices Appoints Dr. Brandi Vann, former U.S. Principal Deputy Assistant Secretary for Nuclear, Chemical, and Biological Defense, to its Board of Directors BOSTON, August 4, 2025 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Dr. Brandi Vann to serve on its Board of Directors. During more than 1 |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 16, 2025 |
908 Devices Appoints Christopher D. Brown to its Board of Directors Exhibit 99.1 908 Devices Appoints Christopher D. Brown to its Board of Directors BOSTON, June 16, 2025 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2025 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 28, 2025 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 908 Devices Inc. Conflict Minerals Report For the Reporting Period from January 1, 2024 to December 31, 2024 Cautionary Note Regarding Forward-Looking Statements This Conflict Minerals Report includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking stat |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT 908 Devices Inc. (Exact name of the registrant as specified in its charter) Delaware 001-39815 (State or other jurisdiction of incorporation or organization) (Commission File Number) 645 Summer Street, Boston, MA 02210 (Address of principal executive offices) (Zip Code) Michael S. Turner C |
|
| May 13, 2025 |
Exhibit 99.1 908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue BOSTON – May 13, 2025 – 908 Devices Inc. (Nasdaq: MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety an |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2025 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| April 28, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 7, 2025 |
As filed with the Securities and Exchange Commission on March 7, 2025 As filed with the Securities and Exchange Commission on March 7, 2025 Registration No. |
|
| March 7, 2025 |
Exhibit 107.1 Filing Fee Table Form S-8 (Form Type) 908 Devices Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2020 Stock Option and Incentive Plan Com |
|
| March 7, 2025 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Company Name Jurisdiction 908 Devices Securities Corporation Massachusetts 908 Devices GmbH Germany 908 Devices (Shanghai) Technology Co., Ltd China CAM2 Technologies, LLC Connecticut |
|
| March 7, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) |
|
| March 7, 2025 |
Exhibit 10.23 SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of March 4, 2025 (the “Amendment Effective Date”), by and between 908 Devices Inc., a Delaware corporation (the “Company”), and Michael S. Turner (the “Executive” and, together with the Company, the “Parties”). Whereas, th |
|
| March 7, 2025 |
Exhibit 10.21 SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of March 4, 2025 (the “Amendment Effective Date”), by and between 908 Devices Inc., a Delaware corporation (the “Company”), and Kevin J. Knopp, Ph.D. (the “Executive” and, together with the Company, the “Parties”). Whereas |
|
| March 7, 2025 |
UNAUDITED PRO FOMA CONDNSED FINANCIAL INFORMATION INDEX TO FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FOMA CONDNSED FINANCIAL INFORMATION INDEX TO FINANCIAL STATEMENTS UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS: Introduction 2 Pro Forma Condensed Consolidated Balance Sheet as of December 31, 2024 (Unaudited) 3 Pro Forma Condensed Consolidated Statement of Operations for the Year Ended December 31, 2024 (Unaudited) 4 Pro Forma Condensed Consolidated Statement of O |
|
| March 7, 2025 |
Exhibit 10.22 SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of March 4, 2025 (the “Amendment Effective Date”), by and between 908 Devices Inc., a Delaware corporation (the “Company”), and Joseph H. Griffith IV (the “Executive” and, together with the Company, the “Parties”). Whereas |
|
| March 7, 2025 |
Exhibit 19 908 DEVICES INC. Insider Trading POLICY This memorandum sets forth the policy of 908 Devices Inc. and any of its future subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Policy”) is designed to prevent insider trading or th |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission file num |
|
| March 4, 2025 |
Exhibit 99.1 908 Devices Announces Strategic Transformation and Reports Fourth Quarter and Full Year 2024 Financial Results Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 BOSTON – March 4, 202 |
|
| March 4, 2025 |
Exhibit 2.1 EXECUTION VERSION SECURITIES AND ASSET PURCHASE AGREEMENT by and among REPLIGEN CORPORATION, REPLIGEN GMBH, and 908 DEVICES INC., dated March 4, 2025 TABLE OF CONTENTS Page Article I PURCHASE AND SALE; CLOSING 1 1.1 Purchase and Sale of Transferred Equity Interests 1 1.2 Purchase and Sale of the Purchased Assets 2 1.3 Assumption of Liabilities. 4 1.4 Non-Assignable Assets; Wrong Pocket |
|
| March 4, 2025 |
Exhibit 99.1 Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices Portfolio includes PAT devices for real-time process monitoring, control and analysis WALTHAM, Mass., and BOSTON – March 4, 2025 – Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld and |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2025 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 14, 2024 |
MASS / 908 Devices Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SC 13G/A 1 fp0090935-1sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* 908 Devices, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 65443P102 (CUSIP Number |
|
| November 14, 2024 |
SC 13G/A 1 arch-sch13g18903.htm ARCH VENTURE FUND VII, L.P. - 908 DEVICES INC. - SCH 13G/A(#4) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* 908 Devices Inc. (Name of Issuer) Common Stock par value $0.001 per share (Title of Class of Securities) 65443P102 (CUSIP Number) September 30, 2024 (Date of E |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File |
|
| November 12, 2024 |
Exhibit 99.1 908 Devices Reports Third Quarter 2024 Financial Results and Updates 2024 Revenue Outlook Revenue increases 17% compared to prior year, driven by recently acquired handheld products BOSTON – November 12, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended September |
|
| August 30, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 30, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 6, 2024 |
Exhibit 99.1 908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook Revenue increases 16% compared to prior year, driven by newly acquired handheld products BOSTON – August 6, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 20 |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 9, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| July 9, 2024 |
UNAUDITED PRO FOMA CONDENSED COMBINED FINANCIAL INFORMATION INDEX TO FINANCIAL STATEMENTS Exhibit 99.4 UNAUDITED PRO FOMA CONDENSED COMBINED FINANCIAL INFORMATION INDEX TO FINANCIAL STATEMENTS UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS: Introduction 2 Pro Forma Condensed Combined Consolidated Balance Sheet as of March 31, 2024 (Unaudited) 3 Pro Forma Condensed Combined Consolidated Statement of Comprehensive Income for the three months Ended March 31, 2024 (Unaudited) 4 Pro For |
|
| July 9, 2024 |
Exhibit 99.3 Cam2 Technologies, LLC Unaudited Condensed Financial Statements As of and for the three months ended March 31, 2024 Table of Contents Unaudited Condensed Financial Statements: Unaudited Condensed Balance Sheet as of March 31, 2024 3 Unaudited Condensed Statement of Income for the three months ended March 31, 2024 4 Unaudited Condensed Statement of Changes in Members’ Equity for the th |
|
| July 9, 2024 |
Cam2 Technologies, LLC Financial Statements As of December 31, 2023 Cam2 Technologies, LLC Exhibit 99.2 Cam2 Technologies, LLC Financial Statements As of December 31, 2023 Cam2 Technologies, LLC Contents Independent Auditor’s Report 3-4 Financial Statements Balance Sheet 6 Statement of Income 7 Statement of Changes in Members’ Equity 8 Statement of Cash Flows 9 Notes to Financial Statements 10-23 2 Independent Auditor’s Report Board of Directors CAM2 Technologies, LLC Danbury, CT Opinio |
|
| June 25, 2024 |
Exhibit 99.1 908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to its Board of Directors BOSTON, June 25, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Admi |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 30, 2024 |
Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 908 Devices Inc. Conflict Minerals Report For the Reporting Period from January 1, 2023 to December 31, 2023 Cautionary Note Regarding Forward-Looking Statements This Conflict Minerals Report includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking stat |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT 908 Devices Inc. (Exact name of the registrant as specified in its charter) Delaware 001-39815 (State or other jurisdiction of incorporation or organization) (Commission File Number) 645 Summer Street, Boston, MA 02210 (Address of principal executive offices) (Zip Code) Michael S. Turner C |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| April 30, 2024 |
Exhibit 99.1 908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook First quarter 2024 product and service revenue increased 8% compared to prior year, driven by a 20% increase in handheld revenue Acquired RedWave Technology, expanding forensics product portfolio for point-of-need applications BOSTON – April 30, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer o |
|
| April 30, 2024 |
Exhibit 2.1 EQUITY PURCHASE AGREEMENT BY AND AMONG 908 DEVICES INC., CAM3 HOLDCO, LLC, CAM2 TECHNOLOGIES, LLC, THE BENEFICIAL SELLERS NAMED HEREIN, AND THE INDIRECT BENEFICIAL SELLER NAMED HEREIN Dated as of April 29, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS 1 Article II PURCHASE AND SALE; CLOSING 14 2.1 Purchase and Sale 14 2.2 Closing 17 2.3 Purchase Price Adjustments 17 2.4 Closing Del |
|
| April 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 30, 2024 |
Exhibit 99.1 908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering Adds optical spectroscopy to the company’s technology platform for point-of-need applications BOSTON – April 30, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biochemical analysis, announces that it has completed the acquisition |
|
| April 30, 2024 |
Exhibit 10.1 [], 2024 908 Devices Inc. 645 Summer St. Boston, MA 02210 Attention: Chief Legal and Administrative Officer Re: Lockup Agreement (the “Agreement”) Ladies and Gentlemen: 1. The undersigned stockholder of 908 Devices Inc., a Delaware corporation (“Purchaser”), understands that Purchaser, the undersigned and certain other parties are entering into a Equity Pu |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 8, 2024 |
Form of First Amendment to Executive Officer Employment Agreement Exhibit 10.18 FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT THIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of [] (the “Amendment Effective Date”), by and between 908 Devices Inc., a Delaware corporation (the “Company”), and [] (the “Executive” and, together with the Company, the “Parties”). Whereas, the Company and Executive ente |
|
| March 8, 2024 |
As filed with the Securities and Exchange Commission on March 8, 2024 As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. |
|
| March 8, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Company Name Jurisdiction 908 Devices Securities Corporation Massachusetts 908 Devices GmbH Germany 908 Devices (Shanghai) Technology Co., Ltd China |
|
| March 8, 2024 |
Exhibit 107.1 Filing Fee Table Form S-8 (Form Type) 908 Devices Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2020 Stock Option and Incentive Plan Com |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 8, 2024 |
Amended and Restated Senior Executive Cash Incentive Bonus Plan Exhibit 10.4 908 DEVICES Inc. AMENDED AND RESTATED SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Bonus Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of 908 Devices Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and inter |
|
| March 8, 2024 |
Exhibit 97 908 Devices inc. COMPENSATION RECOVERY POLICY Adopted as of August 2, 2023 908 Devices Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1.Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons in accordance with |
|
| March 5, 2024 |
Exhibit 99.1 908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook Fourth quarter 2023 revenue increased 23% compared to prior year, driven by handheld revenue increasing 57% BOSTON – March 5, 2024 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported finan |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 5, 2024 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 14, 2024 |
MASS / 908 Devices Inc. / AMERIPRISE FINANCIAL INC - SC 13G Passive Investment SC 13G 1 d931716dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities and Exchange Act of 1934 908 Devices Inc (Name of Issuer) Common Stock (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 14, 2024 |
to Schedule 13G Joint Filing Agreement EX-99.II 3 d931716dex99ii.htm EX-99.II Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2024 in connection with their beneficial ownership of 908 Devices Inc. Columbia Management Investment Advisers, LLC authorizes Ameriprise Financial, Inc. to execute the Schedule 13G to which th |
|
| February 14, 2024 |
MASS / 908 Devices Inc. / GRANAHAN INVESTMENT MANAGEMENT INC/MA Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* 908 Devices, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2023 (Date of Even |
|
| February 14, 2024 |
EX-99.I 2 d931716dex99i.htm EX-99.I Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser – Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940. |
|
| February 14, 2024 |
MASS / 908 Devices Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 eventide908devicessc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* 908 Devices Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of |
|
| February 13, 2024 |
MASS / 908 Devices Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0157-908devicesinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: 908 Devices Inc Title of Class of Securities: Common Stock CUSIP Number: 65443P102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which th |
|
| February 9, 2024 |
SC 13G/A 1 arch-sch13g18793.htm ARCH VENTURE FUND VII, L.P. - 908 DEVICES INC. - SCH 13G/A(#3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* 908 Devices Inc. (Name of Issuer) Common Stock par value $0.001 per share (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2023 (Date of Ev |
|
| January 29, 2024 |
MASS / 908 Devices Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* 908 Devices Inc. (Name of Issuer) Common stock (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 13, 2023 |
MASS / 908 Devices Inc / ALGER ASSOCIATES INC - 908 DEVICES INC Passive Investment 908 Devices Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* 908 Devices Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65443P102 (CUSIP Number) October 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| November 7, 2023 |
908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook Exhibit 99.1 908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook BOSTON – November 7, 2023 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended September 30, 2023. "We are pleased with the step-up in our revenues from the second q |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2023 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| August 8, 2023 |
Exhibit 10.1 DEFAULT WAIVER AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This DEFAULT WAIVER AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of August 4, 2023, by and between SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge B |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2023 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 8, 2023 |
Exhibit 99.1 908 Devices Reports Second Quarter 2023 Financial Results and Updates 2023 Revenue Outlook Revenue increases 9% compared to prior year, driven by handheld revenue growth of 27% BOSTON – August 8, 2023 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended J |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2023 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 9, 2023 |
Exhibit 99.1 908 Devices Reports First Quarter 2023 Financial Results and Reiterates 2023 Revenue Outlook Q1 2023 revenue increases 14% compared to prior year with recurring revenue growing 67% BOSTON, MA – May 9, 2023 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter en |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 1, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 15, 2023 |
Exhibit 107.1 Filing Fee Table Form S-8 (Form Type) 908 Devices Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2020 Stock Option and Incentive Plan Com |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 15, 2023 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Company Name Jurisdiction 908 Devices Securities Corporation Massachusetts 908 Devices GmbH Germany 908 Devices (Shanghai) Technology Co., Ltd China |
|
| March 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2023 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 7, 2023 |
Exhibit 99.1 908 Devices Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Revenue Outlook Full Year 2022 revenue increases 11% compared to prior year with desktop revenue increasing 25% BOSTON, MA – March 7, 2023 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial res |
|
| February 14, 2023 |
MASS / 908 Devices Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 eventide908devicessc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 908 Devices Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this S |
|
| February 14, 2023 |
MASS / 908 Devices Inc. / ALGER ASSOCIATES INC - 908 DEVICES INC. Passive Investment SC 13G/A 1 d421921dsc13ga.htm 908 DEVICES INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* 908 Devices Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 13, 2023 |
SC 13G/A 1 arch-sch13g18696.htm ARCH VENTURE FUND VII, L.P. - 908 DEVICES INC. - SCH 13G/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* 908 Devices Inc. (Name of Issuer) Common Stock par value $0.001 per share (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2022 (Date of Ev |
|
| February 10, 2023 |
MASS / 908 Devices Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| November 14, 2022 |
Exhibit 99.1 908 Devices Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Outlook Q3 2022 revenue increases 26% over prior year, with gross margin of 59% BOSTON, MA – November 14, 2022 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter en |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 14, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File |
|
| November 8, 2022 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date between SILICON VALLEY BANK, a California corporation (?Bank?), and the borrower listed on Schedule I hereto (?Borrower?). The parties agree as follows: 1.????????????????? LOAN AND TERMS OF PAYMENT ? 1.1??????????????? Revolving Line. ? (a)????????????????Availability. Su |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File |
|
| October 11, 2022 |
MASS / 908 Devices Inc. / ALGER ASSOCIATES INC - 908 DEVICES INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 908 Devices Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 65443P102 (CUSIP Number) September 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| August 9, 2022 |
Exhibit 99.1 908 Devices Reports Second Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook Q2 2022 revenue increases 34% over prior year, with gross margin of 60% BOSTON, MA ? August 9, 2022 ? 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter end |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 17, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 18, 2022 |
CORRESP 1 filename1.htm May 18, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: 908 Devices Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-264828 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), 908 Devices Inc |
|
| May 10, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) 908 Devices Inc. |
|
| May 10, 2022 |
As filed with the Securities and Exchange Commission on May 10, 2022. S-3 1 tm2214740-1s3.htm S-3 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 10, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 908 DEVICES INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorp |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 10, 2022 |
Form of Senior Indenture between the Registrant and one or more trustees to be named Exhibit 4.6 908 DEVICES INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 |
|
| May 10, 2022 |
Exhibit 99.1 908 Devices Reports First Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook Q1 2022 revenue increases 50% over prior year with Desktop revenue in BioPharma growing 68% BOSTON, MA ? May 10, 2022 ? 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results fo |
|
| May 10, 2022 |
Form of Subordinated Indenture between the Registrant and one or more trustees to be named Exhibit 4.7 908 DEVICES INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certifi |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ?? Check the appropriate box: ?????????????Preliminary Proxy Statement ?????????????Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 21, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 11, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 11, 2022 |
As filed with the Securities and Exchange Commission on March 11, 2022 As filed with the Securities and Exchange Commission on March 11, 2022 Registration No. |
|
| March 11, 2022 |
Subsidiaries of the Registrant Exhibit 21.1 ? SUBSIDIARIES OF THE REGISTRANT ? Company Name Jurisdiction 908 Devices Securities Corporation Massachusetts ? |
|
| March 11, 2022 |
Exhibit 10.5 ? 908 Devices Inc. ? Amended and Restated Non-Employee Director Compensation Policy ? The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of 908 Devices Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or |
|
| March 11, 2022 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) 908 Devices Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2020 Stock Option and Inc |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 7, 2022 |
Exhibit 99.1 908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook 2021 revenue increases 57% year over year BOSTON, MA ? March 7, 2022 ? 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter and full year ended De |
|
| March 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 2, 2022 |
908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors Exhibit 99.1 908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors BOSTON, March 2, 2022 ? 908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (Nasdaq: RGEN), to serve on its Board of Directors effective im |
|
| February 10, 2022 |
MASS / 908 Devices Inc. / Razor's Edge Fund, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* 908 Devices Inc. (Name of Issuer) Common Stock par value $0.001 per share (Title of Class of Securities) 65443P 102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 10, 2022 |
MASS / 908 Devices Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 9, 2022 |
MASS / 908 Devices Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* 908 Devices, Inc. (Name of Issuer) Common Stock par value $0.001 per share (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p |
|
| January 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2022 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 10, 2022 |
Exhibit 99.1 908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021 Full year 2021 revenue growth of at least 54% compared to 2020 BOSTON, MA ? January 9, 2022 ? 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced preliminary, unaudited revenue for the fourth quarter |
|
| November 12, 2021 |
3,150,000 Shares 908 Devices Inc. Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(4)? ?Registration Statement No. 333-260865? PROSPECTUS 3,150,000 Shares 908 Devices Inc. Common Stock We are offering 3,150,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol ?MASS.? On?November 10, 2021, the last reported sale price of our common stock on the Nasdaq Global Market was $32.32 per s |
|
| November 8, 2021 |
As filed with the Securities and Exchange Commission on November 8, 2021. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 8, 2021. |
|
| November 8, 2021 |
November 8, 2021 Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: 908 Devices Inc. Registration Statement on Form S-1 (File No. 333-260865) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advis |
|
| November 8, 2021 |
November 8, 2021 Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re:??????????908 Devices Inc. Registration Statement on Form S-1 (File No. 333-260865) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the ?Act?), 908 Devices Inc. (the ?Company?) |
|
| November 8, 2021 |
Form of Underwriting Agreement EX-1.1 2 tm2112538d3ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 [●] Shares 908 Devices Inc. Common Stock UNDERWRITING AGREEMENT , 2021 Cowen and Company, LLC SVB Leerink LLC As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Dear Sirs and Madams: 1. Introd |
|
| November 4, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 4, 2021 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 4, 2021 |
Exhibit 99.1 908 Devices Reports Third Quarter 2021 Financial Results Sequential revenue growth of more than 50% compared to Q2 2021 Year-to-date product and service revenue growth of 36% compared to the same period of 2020 BOSTON, MA ? November 4, 2021 ? 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today |
|
| September 10, 2021 |
MASS / 908 Devices Inc. / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2021 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 4, 2021 |
Exhibit 99.1 908 Devices Reports Second Quarter 2021 Financial Results and Raises 2021 Revenue Outlook Increased 2021 revenue guidance projects 54% annual revenue growth at the midpoint of the range BOSTON, MA ? August 4, 2021 ? 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results |
|
| June 23, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 908 DEVICES INC. |
|
| June 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 8, 2021 |
Exhibit 99.1 908 Devices Appoints Marcia Eisenberg, Ph.D., Chief Scientific Officer, Labcorp Diagnostics, to its Board of Directors Third Board appointment of 2021 supports long-term vision for the company?s technology platform BOSTON, June 8, 2021 ? 908 Devices (NASDAQ: MASS), a pioneer of purpose-built, handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has ap |
|
| May 13, 2021 |
Exhibit 99.1 908 Devices Reports First Quarter 2021 Financial Results and Reiterates 2021 Revenue Outlook Q1 2021 Product and Service Revenue Increased More Than 100% Over Prior Year BOSTON, MA ? May 13, 2021 ? 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter e |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2021 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 30, 2021 |
TABLE OF CONTENTS Confidential Treatment Requested by 908 Devices Inc. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted with the Securities and Exchange Commission on April 30, 2021. This draft registration statement has not been publicly filed with the Securities Exchange Commission and all information herein remains strictly confidential. Registration No. 333-????????? ? ? UNITED |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???????? ??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitt |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39815 908 DEVICES IN |
|
| March 31, 2021 |
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the general terms and provisions of the registered capital stock of 908 Devices Inc. (?908 Devices?, ?we?, ?our? or ?us?) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Sixth Amended and Resta |
|
| March 31, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Company Name Jurisdiction 908 Devices Securities Corporation Massachusetts |
|
| March 31, 2021 |
Non-Employee Director Compensation Policy Exhibit 10.5 Non-Employee Director Compensation Policy The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of 908 Devices Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (?non-employee directors?). |
|
| March 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 30, 2021 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 30, 2021 |
Exhibit 99.1 908 Devices Reports Fourth Quarter and Full Year 2020 Financial Results and Provides 2021 Revenue Outlook 2020 Revenue Increased 50% Over Prior Year BOSTON, MA – March 30, 2021 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter and full year ended |
|
| March 15, 2021 |
EX-10.1 2 tm219505d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Certain information in this document identified by bracketed asterisks ([***]) has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 908 DEVICES INC. SIGNATURE BANK AMENDED AND RESTATED LOAN AND SECURITY AGREEME |
|
| March 15, 2021 |
8-K 1 tm219505d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2021 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of in |
|
| February 23, 2021 |
8-K 1 tm217595d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 001-39815 45-4524096 (State or other jurisdiction of |
|
| February 23, 2021 |
Exhibit 99.1 908 Devices Appoints Jeff George and Fenel Eloi to its Board of Directors Company adds two directors with financial, pharmaceutical, and consumable business expertise Boston, MA ? February 23, 2021 ? 908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it has appointed Jeff George and |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 908 Devices Inc. (Name of Issuer) Common Stock par value $0.001 per share (Title of Class of Securities) 65443P 102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 908 Devices Inc. (Name of Issuer) Common Stock par value $0.001 per share (Title of Class of Securities) 65443P102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| December 26, 2020 |
As filed with the Securities and Exchange Commission on December 23, 2020 Registration No. |
|
| December 18, 2020 |
6,500,000 Shares 908 Devices Inc. Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-250954 PROSPECTUS 6,500,000 Shares 908 Devices Inc. Common Stock We are offering 6,500,000 shares of our common stock. This is our initial public offering and no public market currently exists for our common stock. The initial public offering price is $20.00 per share. Prior to this offering, there has been no public market |
|
| December 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware 45-4524096 (State of incorporation or organization) (I.R.S. Employer Identification No.) 645 Summer Street Boston, M |
|
| December 17, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 17, 2020. |
|
| December 17, 2020 |
As filed with the Securities and Exchange Commission on December 17, 2020 Registration No. |
|
| December 16, 2020 |
Exhibit 10.7 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. LIMITED EXCLUSIVE COMMERCIAL FIELD OF USE PATENT LICENSE AGREEMENT This Exclusive Commercial Patent License Agreement is between UT-Battelle, LLC (UT-Battelle |
|
| December 16, 2020 |
As filed with the Securities and Exchange Commission on December 16, 2020. Registration No. 333-250954 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizatio |
|
| December 16, 2020 |
Exhibit 10.6 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This Amended and Restated Exclusive License Agreement (the ‘‘Agreement”) is entered into as of this 20th day |
|
| December 16, 2020 |
Exhibit 10.9 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 908 DEVICES INC. SIGNATURE BANK LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this "Agreement") is entered into as of August 29, 2019 by and b |
|
| December 16, 2020 |
Exhibit 10.8 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. PLA-1669 LIMITED EXCLUSIVE COMMERCIAL FIELD OF USE PATENT LICENSE AGREEMENT This Exclusive Commercial Patent License Agreement is between UT-Battelle, LLC (UT |
|
| December 15, 2020 |
[Remainder of page left intentionally blank] VIA EDGAR December 15, 2020 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| December 15, 2020 |
December 15, 2020 Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: 908 Devices Inc. Registration Statement on Form S-1 (File No. 333-250954) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, as amended, we wish to advi |
|
| December 14, 2020 |
Exhibit 10.1 908 DEVICES INC. 2012 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the 908 Devices Inc. 2012 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of 908 Devices Inc., a Delaware corporation (including any successor ent |
|
| December 14, 2020 |
Exhibit 4.7 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| December 14, 2020 |
Warrant Agreement, dated August 29, 2019, between Signature Holdco, LLC and the Registrant Exhibit 4.8 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH APPLICABLE LAW. WARRANT TO PURCHASE STOCK Company: 908 DEVICES INC. (“Company”) Number of Shares: 35,771 Type/Series of Stock: Series |
|
| December 14, 2020 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 908 DEVICES INC. 908 Devices Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on February 10, 2012 under th |
|
| December 14, 2020 |
Exhibit 4.6 THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONA |
|
| December 14, 2020 |
Exhibit 10.13 908 DEVICES INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the 908 Devices Inc. 2020 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of 908 Devices Inc. (the “Company”) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). An aggr |
|
| December 14, 2020 |
Warrant Agreement, dated March 6, 2014, between SVB Financial Group and the Registrant Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| December 14, 2020 |
Exhibit 10.4 INDEMNIFICATION AGREEMENT (For Officers of a Delaware Corporation) This Indemnification Agreement (“Agreement”) is made as of by and between 908 Devices Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in order to |
|
| December 14, 2020 |
Subsidiaries of the Registrant EXHIBIT 21.1 SUBSIDIARIES OF THE REGISTRANT None. |
|
| December 14, 2020 |
Exhibit 4.3 .ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.001 COMMON STOCK Certificate Number ZQ00000000 THIS CERTIFIES THAT 908 DEVICES INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexa |
|
| December 14, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 14, 2020. |
|
| December 14, 2020 |
Warrant Agreement, dated June 23, 2015, between SVB Financial Group and the Registrant Exhibit 4.5 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| December 14, 2020 |
Exhibit 10.14 908 DEVICES Inc. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the “Bonus Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of 908 Devices Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to those of the |
|
| December 14, 2020 |
Exhibit 10.2 908 DEVICES INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the 908 Devices Inc. 2020 Stock Option and Incentive Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of 908 Devices Inc. (the “Company”) and |
|
| December 14, 2020 |
Exhibit 3.5 AMENDED AND RESTATED BY-LAWS OF 908 DEVICES INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subseq |
|
| December 14, 2020 |
Form of Underwriting Agreement Exhibit 1.1 [●] Shares 908 Devices Inc. Common Stock UNDERWRITING AGREEMENT , 2020 Cowen and Company, LLC SVB Leerink LLC As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Dear Sirs and Madams: 1. Introductory. 908 Devices Inc., a Delaware corpo |
|
| December 14, 2020 |
Exhibit 10.3 INDEMNIFICATION AGREEMENT (For Directors of a Delaware Corporation) This Indemnification Agreement (“Agreement”) is made as of by and between 908 Devices Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in order t |
|
| December 4, 2020 |
Michael J. Minahan Goodwin Procter LLP +1 617 570 1021 100 Northern Avenue [email protected] Boston, MA 02210 goodwinlaw.com +1 617 570 1000 December 4, 2020 CERTAIN PORTIONS OF THIS LETTER HAVE BEEN OMITTED FROM THE VERSION FILED VIA EDGAR. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS |
|
| December 1, 2020 |
As filed with the Securities and Exchange Commission on December 1, 2020. Registration No. 333-250954 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 908 Devices Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization |
|
| December 1, 2020 |
Fifth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 908 DEVICES INC. 908 Devices Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware on February 10, 2012 under the name “9 |
|
| December 1, 2020 |
By-laws of the Registrant, as currently in effect Exhibit 3.4 BY-LAWS of 908 DEVICES INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting is established or said meeting is n |
|
| December 1, 2020 |
Exhibit 10.8 PLA-1669 LIMITED EXCLUSIVE COMMERCIAL FIELD OF USE PATENT LICENSE AGREEMENT This Exclusive Commercial Patent License Agreement is between UT-Battelle, LLC (UT-Battelle), a Tennessee non-profit limited liability company (“Licensor”), and 908 Devices Inc., a Delaware corporation having an address at 27 Drydock Avenue, 8th Floor, Boston, MA 02210 (“Licensee”), hereinafter referred to sin |
|
| December 1, 2020 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 908 DEVICES INC. 908 Devices Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 1. Pursuant to Section 242 of the DGCL, this Certificate of Amendment to the Fifth Amended and Res |
|
| December 1, 2020 |
Exhibit 10.6 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT This Amended and Restated Exclusive License Agreement (the ‘‘Agreement”) is entered into as of this 20th day of May, 2015 (the “Restatement Effective Date”) between The University of North Carolina at Chapel Hill having an address at 100 Europa Drive, Suite 430, Chapel Hill, North Carolina, 27517 (“University”) and 908 Devices Inc., a c |
|
| December 1, 2020 |
Exhibit 10.1 908 DEVICES INC. 2012 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the 908 Devices Inc. 2012 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of 908 Devices Inc., a Delaware corporation (including any successor ent |
|
| December 1, 2020 |
Exhibit 10.7 LIMITED EXCLUSIVE COMMERCIAL FIELD OF USE PATENT LICENSE AGREEMENT This Exclusive Commercial Patent License Agreement is between UT-Battelle, LLC (UT-Battelle), a Tennessee non-profit limited liability company (“Licensor”), and 908 Devices inc., a Delaware corporation having an address at 27 Drydock Avenue, 8th Floor, Boston, MA 02210 (“Licensee”), hereinafter referred to singly as th |
|
| November 25, 2020 |
Form of Director Indemnification Agreement Exhibit 10.3 GP Draft dated November 20, 2020 INDEMNIFICATION AGREEMENT (For Directors of a Delaware Corporation) This Indemnification Agreement (“Agreement”) is made as of by and between 908 Devices Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve |
|
| November 25, 2020 |
Exhibit 10.11 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of August 7, 2020, |
|
| November 25, 2020 |
Exhibit 3.3 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 908 DEVICES INC. 908 Devices Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is 908 Devices Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Dela |
|
| November 25, 2020 |
Exhibit 4.1 FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT By and Among 908 Devices Inc. Other Stockholders as defined herein and the Investors as defined herein Dated as of April 11, 2019 Table of Contents Page ARTICLE I - DEFINITIONS 1 Section 1.1 Construction of Terms 1 Section 1.2 Terms Not Defined 1 Section 1.3 Number of Shares of Stock 1 Section 1.4 Defined Terms 2 ARTICLE II - REPRESENT |
|
| November 25, 2020 |
Exhibit 4.2 FOURTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This FOURTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is dated as of April 12, 2019, by and among 908 Devices Inc., a Delaware corporation (the “Company”), and the persons identified on the signature pages hereto (collectively, the “Investors,” and each individually, an “Investor”). WHEREAS, the partie |
|
| November 25, 2020 |
Form S-1, as amended (File No. 333-250954) TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 25, 2020. |
|
| November 25, 2020 |
Form of Executive Officer Employment Agreement Exhibit 10.5 MODEL EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between 908 Devices Inc. a Delaware corporation (the “Company”), and (“You”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). [Excep |
|
| November 25, 2020 |
Michael J. Minahan +1 617 570 1021 [email protected] Goodwin Procter llp 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 November 25, 2020 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: 908 Devices Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted |
|
| November 25, 2020 |
Loan and Security Agreement between the Registrant and Signature Bank, dated August 29, 2019 Exhibit 10.9 908 DEVICES INC. SIGNATURE BANK LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this "Agreement") is entered into as of August 29, 2019 by and between SIGNATURE BANK ("Bank") and 908 DEVICES INC. ("Borrower"). RECITALS Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement sets forth the terms on which |
|
| November 25, 2020 |
Form of Executive Officer Indemnification Agreement Exhibit 10.4 GP Draft dated November 20, 2020 INDEMNIFICATION AGREEMENT (For Officers of a Delaware Corporation) This Indemnification Agreement (“Agreement”) is made as of by and between 908 Devices Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve |
|
| November 25, 2020 |
Exhibit 10.12 LEASE BETWEEN BOSTON HARBOR INDUSTRIAL DEVELOPMENT LLC AND 908 DEVICES INC. ARTICLE 1 Reference Data 1.1 Introduction: Each reference in this Lease to any of the following subjects shall be construed to incorporate the data stated for that subject in this Section 1.1. Lease Date: As of January 2, 2018 Building: The building located at 645 Summer Street, Boston, MA, containing approxi |
|
| November 25, 2020 |
Exhibit 10.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this "Amendment") is entered into as of March 15, 2020, b |
|
| November 25, 2020 |
Exhibit 3.5 AMENDED AND RESTATED BY-LAWS OF 908 DEVICES INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subseq |
|
| November 25, 2020 |
2020 Stock Option and Incentive Plan and forms of award agreements thereunder Exhibit 10.2 908 DEVICES INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the 908 Devices Inc. 2020 Stock Option and Incentive Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of 908 Devices Inc. (the “Company”) and |
|
| November 6, 2020 |
TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on November 6, 2020. |
|
| November 6, 2020 |
Michael J. Minahan Goodwin Procter LLP +1 617 570 1021 100 Northern Avenue [email protected] Boston, MA 02210 goodwinlaw.com +1 617 570 1000 November 6, 2020 Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: 908 Devices Inc. Draft Registration Statement on Form S-1 Submitted October 2, 2020 CIK |
|
| October 2, 2020 |
TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on October 2, 2020. |
